PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.

ABSTRACT:

Background

PD-L1 tumor expression has been associated with poor prognosis in a variety of solid tumors, including lung cancer, and represents a validated target for immune checkpoint inhibition in advanced malignances. It remains unknown, however, if PD-L1 can be used to predict survival in early stage, surgically treated cancers. This meta-analysis compares PD-L1 tumor expression and long term survival after surgical resection in early non-small cell lung cancer (NSCLC).

Methods

PubMed was searched to identify eligible studies that compared survival of surgically resected stage I-III NSCLC patients according to PD-L1 tumor expression. Included studies were grouped according to measurement criteria of PD-L1 expression: 1%, 5%, 50% cutoffs or H-score. Meta-analysis was perfor

SUBMITTER: Tuminello S 

PROVIDER: S-EPMC7481631 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature